Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies (TITANium)

NCT06542250 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06542250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06542250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies (TITANium)
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 18, 2024
Completion date
December 18, 2029
Enrollment
174 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell malignancies